Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
NCT00062660
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Tipranavir
Sponsor
Boehringer Ingelheim